Are there any estimates for the Nexavar and Kyprolis revenues?
A few days ago S&P started coverage with a buy rating and PT of 105. Today the Maxim Group increased its PT from $95 to $105. And yet, the price declined from $93 to below $80 in approximately one week.
Perhaps the old-timers of this board could provide some reassuring guidance.